Drug Patents owned by Durect

1. List of Posimir drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8753665 DURECT Controlled delivery system
Sep, 2025

(2 years from now)

US8846072 DURECT Controlled delivery system
Sep, 2025

(2 years from now)

US8153661 DURECT Controlled delivery system
Sep, 2025

(2 years from now)

US8153149 DURECT Controlled delivery system
Sep, 2025

(2 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Feb 1, 2024

Drugs and Companies using BUPIVACAINE ingredient

Market Authorisation Date: 01 February, 2021

Treatment: Method for providing sustained local anesthesia for at least 24 hours

Dosage: SOLUTION, EXTENDED RELEASE;INFILTRATION

More Information on Dosage

POSIMIR family patents

14

United States

4

European Union

3

Denmark

3

Slovenia

3

Portugal

3

Cyprus

3

Spain

3

Poland

2

Korea, Republic of

2

Japan

EA

2

EA

1

Israel

1

South Africa

1

Austria

1

Mexico

1

Australia

1

Hong Kong

1

Russia

1

Lithuania

1

Hungary

1

Norway

1

Brazil

1

Croatia

1

RS

1

China

1

Georgia

1

Ukraine

1

Canada

1

New Zealand

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in